Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study

Fig. 4

Gefitinib inhibits tumor cell growth in EGFR mutant PDX model and its corresponding primary cell. a Gefitinib (100 mg/kg) significantly suppresses tumor growth in an EGFR mutant PDX LG1. Mice were divided into two different groups as described in Materials and Methods. The asterisks (**, ***) indicate a significant (p < 0.01, p < 0.001, respectively). b Gefitinib (100 mg/kg) have no effective on tumor growth in EGFR wild type PDX LG50. Mice were divided into two different groups as described in Materials and Methods. There is no statistical significance in tumor volume compared to the vehicle-treated control (p > 0.05). c Gefitnib suppresses LG1 primary cell proliferation and have no effection on the LG50 primary cell proliferation. LG1 primary cells and LG50 primary cells were treated with different doses of gefitinib (0, 0.25, 0.5 and 1 μM), and proliferation was measured by CCK8 assay Significant differences were evaluated using a 2-way ANOVA to determine significant time and dose effects. The asterisks (**, ***) indicate a significant (p < 0.01, p < 0.001, respectively). There was no significant differences in the LG50 cell proliferation. The morphological characteristic was obseved by microscopes (Bar:100 μm)

Back to article page